Natixis Vaxart, Inc. Transaction History
Natixis
- $17.6 Billion
- Q3 2024
Shares
3 transactions
Others Institutions Holding VXRT
# of Institutions
107Shares Held
37.7MCall Options Held
188KPut Options Held
180K-
Sio Capital Management, LLC New York, NY13.6MShares$9.25 Million6.11% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$6.85 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.97MShares$2.7 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.54MShares$1.73 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.77MShares$1.21 Million0.0% of portfolio
About Vaxart, Inc.
- Ticker VXRT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 126,506,000
- Market Cap $86M
- Description
- Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1...